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Plasma concentrations of atrial natriuetic peptide (ANP), one of the key hormones
involved in the regulation of body fluid and blood pressure,
1 have been shown to
be correlated with the severity of acute lung injury.
2 A recently published study
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Purpose: Atrial natriuretic peptide (ANP) has a variety of pharmacologic effects,
including natriuresis, diuresis, vasodilatation, and suppression of the renin-
angiotensin system. A recent study showed that ANP infusion improved
hypoxemia and pulmonary hypertension in a lung injury model. On the other
hand, the pulse contour cardiac output (PiCCO
TM) system (Pulsion Medical
Systems, Munich, Germany) allows monitoring of the intravascular volume status
and may be used to guide volume therapy in severe sepsis and critically ill
patients. Materials and Methods: We treated 10 pulmonary edema patients
without heart disease with human ANP (HANP). The patients were divided into
two groups: a group with normal Intrathoracic Blood Volume (ITBV) (900-1100
mL/m
2) (n = 6), and a group with abnormal ITBV (n = 4), as measured by the
PiCCO
TM device; the extravascular lung water (EVLW) and pulmonary vascular
permeability index (PVPI) in the two groups were compared. Results: The
average patient age was 63.9  ± 14.4 years. The normal ITBV group showed
significant improvement of the EVLW (before, 16.7 ± 2.7 mL/kg; after, 10.5 ± 3.6
mL/kg; p = 0.0020) and PVPI (before, 3.2 ± 0.3; after, 2.1 ± 0.7; p = 0.0214) after
the treatment. The abnormal ITBV group showed no significant improvement of
either the EVLW (before, 16.3 ± 8.9 mL/kg; after, 18.8 ± 9.6 mL/kg; p = 0.8387)
or PVPI (before, 2.3 ± 0.8; after, 2.7 ± 1.3; p = 0.2782) after the treatment. In both
groups, the EVLW and PVPI were strongly correlated with the chest X-ray
findings. Conclusion: We conclude that HANP supplementation may improve the
EVLW and PVPI in pulmonary edema patients without heart disease with a
normal ITBV. The PiCCO
TM system seems to be a useful device for the manage-
ment of pulmonary edema.
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INTRODUCTIONreported that significant diuresis associated with an increase
in the plasma ANP levels preceded the improvement of
pulmonary function in patients with infantile respiratory
distress syndrome.
3,4 ANP has a variety of pharmacologic
effects, including natriuresis, diuresis, vasodilatation, and
suppression of the renin-angiotensin system. A previous
study showed that ANP infusion improved hypoxemia and
pulmonary hypertension in a lung injury model.
5 In respect
of clinical reports, Mitaka, et al.
6 suggested that ANP
infusion induces diuresis and improves the pulmonary gas
exchange in patients with acute lung injury during mecha-
nical ventilation using positive end-expiratory pressure.
Sumi, et al.
7 showed that ANP may be a useful therapeutic
choice for the control of pulmonary circulation during
abdominal aortic surgery.
On the other hand, the pulse contour cardiac output
(PiCCO
TM) system (Pulsion Medical Systems) allows
monitoring of the intravascular volume status and may be
used to guide volume therapy in severe sepsis and criti-
cally ill patients. The extravascular lung water (EVLW)
volume has also been demonstrated to be well correlated
with the oxygenation level in septic shock patients with
acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS).
8
We treated 10 pulmonary edema patients without heart
disease with human ANP (HANP). We administered HANP
at the dose of 0.1 µg/kg/min by intravenous injection. All the
patients were hemodynamically stabilized and mechani-
cally ventilated and sedated. A thermo-fiber-optic catheter
was inserted into the femoral or brachiocephalic artery in
each patient (Pulsiocath 4F, PV 2024L, Pulsion Medical
Systems, Munich, Germany), and the catheter was connect-
ed to a bed box and a computer system (Cold-Z021, Pulsion
Medical Systems, Munich, Germany). The PiCCO system
can be used to measure any physiological parameter,
including Intrathoracic Blood Volume (ITBV), extravas-
cular lung water (EVLW), and the pulmonary vascular
permeability index (PVPI) (Table 1). Classification of
pulmonary edema using PVPI as measured using the
PiCCO system is shown in Fig. 1.
The patients were divided into two groups: a group with
normal ITBV (900-1,100 mL/m
2) (n = 6) and a group with
abnormal ITBV (n = 4), as measured with the PiCCO
TM
device. The EVLW and PVPI in the two groups were
compared. The study was conducted with the approval of
our institution’s ethics committee and informed consent
from each patient was obtained prior to the start of the
study. Differences were analyzed using the Wilcoxon’s
generalized test. p-values less than 0.05 were regarded as
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MATERIALS AND METHODS 
Table 1.Parameters Measured with the PiCCO-Technology
Thermodilution parameters
Cardiac output CO
Global end-diastolic volume GEDV
Intrathoracic blood volum ITBV
Extravascular lung water EVLW
Pulmonary vascular permeability index  PVPI
Cardiac function index CFI
Global ejection fraction GEF
Pulse contour parameters
Pulse contour cardiac output PCCO
Arterial blood pressure AP
Heart rate HR
Stroke volume SV
Stroke volume variation SVV
Pulse pressure variation PPV
Systemic vascular resistance SVR
Index of left ventricular contractility dPmx
The pulse contour cardiac output (PiCCO) system can be used to measure 
any cardiopulmonary parameter.
Fig. 1. Classification of pulmonary edema based on the IBPV as measured using
the PiCCO system. Results of categorization by the PiCCO system, of pulmonary
edema patients in whom a precise diagnosis of pulmonary edema could not be
made. IBPV, Intrathoracic Blood Volume; PiCCO, pulse contour cardiacoutput.
Table 2.Patient Characteristics
Characteristics Data
No. of patients 10
SEX (male / female) 8 / 2
Age (yrs), mean ± SE 63.9 ± 15.4
Outcome (survival / expired)  6 / 4
Underlying disease
Sepsis (pneumonia etc) 5
Trauma 3
Burn 1
Liver failure 1denoting statistical significance.
We treated 10 pulmonary edema patients without heart
disease with HANP. The average patient age was 63.9 ±
14.4 years; 8 of the patients were men and 2 were women.
The major underlying disease was sepsis in all the patients
(Table 2). The pretreatment vital signs and laboratory data
was not significantly different between the normal and
abnormal ITBV groups (Table 3). The change of the ITBV
after HANP administration in each case is shown in Table
4. The normal ITBV group showed significant improve-
ment of the EVLW (before, 16.7 ± 2.7 mL/kg; after, 10.5 ±
3.6 mL/kg; p = 0.0020) and PVPI (before, 3.2 ± 0.3; after,
2.1 ± 0.7; p = 0.0214) after the HANP treatment (Tables 5
and 6). The abnormal ITBV group showed no significant
improvement of either the EVLW (before, 16.3 ± 8.9 mL/kg;
after, 18.8 ± 9.6 mL/kg; p = 0.8387) or PVPI (before, 2.3 ±
0.8; after, 2.7 ± 1.3; p = 0.2782) after the HANP treatment
(Tables 5 and 6). None of the patients of the normal ITBV
group were given any other diuretic agents. On the other
hand, two patients (case 8 and 10) of the abnormal ITBV
group were given the diuretic furosemide as needed. In
regard to the administration of vasopressor agents, norad-
renalin (0.1-0.05γ) was administered to 5 patients (Cases 2,
3, 4, 9 and 10). Dopamine, which may also have the effect
of facilitating diuresis, was not administered to any of the
patients. 
In both groups, the EVLW and PVPI were strongly
correlated with the chest X-ray findings. We confirmed
that the normal ITBV cases showed improvement of the
EVLW and that the PaO2/FiO2 ratio correlated well with
the improvement of the chest X-ray permeability findings
(Figs. 2 and 3). On the other hand, the abnormal ITBV
cases showed no improvement of the EVLW, and the
PaO2/FiO2 ratio was not correlated with the chest X-ray
Yuichiro Sakamoto, et al.
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Table 3.Pretreatment Vital Sign and Laboratory Data
ITBV normal group   ITBV abnormal group pvalue
Systolic blood pressure (mmHg) 116.7 ± 13.7 132.5 ± 15.0 NS
Pulse rate (/min) 92.5 ± 19.7 98.8 ± 12.5 NS
PaO2/FiO2 217.0 ± 27.3 166.4 ± 38.1 NS
Blood urea nltrogen (mg/dL) 17.8 ± 10.1 27.6 ± 9.9 NS
Creatinine (mg/dL) 1.2 ± 0.5 0.9 ± 0.2 NS
White blood cell (/uL) 10190 ± 4040 9328 ± 2349 NS
Hemoglobin (g/dL) 10.0 ± 1.3 10.5 ± 1.3 NS
Platelet (×10
4/uL) 14.1 ± 6.5 11.2 ± 4.4 NS
ITBV, intrathoracic blood volume.





Case 1 941 975
Case 2 905 727
Case 3 1,021 1,265
Case 4 969 870
Case 5 929 719
Case 6 953 879
Average 953.0 ± 44.5 906 ± 201 NS
ITBV abnormal group
Case 7 1,214 1,575
Case 8 1,559 1,397
Case 9 1,131 1,181
Case 10 1,415 847
Average 1329.80 ± 193.8 1250.0 ± 156.6 NS
ITBV, intrathoracic blood volume.
RESULTSpermeability findings (Figs. 4 and 5).
A previous study showed that HANP treatment improved
the arterial oxygenation and lung injury score in patients
with acute lung injury during mechanical ventilation using
positive end-expiratory pressure (PEEP).
6 The following
mechanisms are speculated to underlie the effectiveness of
HANP in cases of lung injury. HANP directly improves




11 A recent study reported that HANP treatment
during aortic clamping and abdominal aortic aneurysmec-
tomy attenuated the rises in pulmonary artery pressure and
vascular resistance without producing severe systemic
hypotension.
7 However, several studies have also suggested
that HANP treatment is not effective for pulmonary edema
not associated with heart disease. Therefore, the criteria for
the administration of HANP for pulmonary edema not
associated with heart disease has not been established. This
study showed that HANP supplementation may improve
the EVLW and PVPI in pulmonary edema patients with-
out heart disease with a normal ITBV. We propose that
pulmonary edema patients without heart disease with an
abnormal ITBV be treated using other strategies, namely
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Table 5.Change of EVLW after Carperitide Therapy 
Case Before (mL/kg) After (mL/kg) pvalue
ITBV normal group
Case 1 16.0 10.0
Case 2 19.0 12.0
Case 3 14.0 8.0
Case 4 15.0 13.0
Case 5 15.0 5.0
Case 6 21.0 15.0
Average 16.7 ± 2.7 10.5 ± 3.6 NS
ITBV abnormal group
Case 7 12.0 13.0
Case 8 29.0 33.0
Case 9 10.0 13.0
Case 10 22.0 16.0
Average 16.3 ± 8.9 18.8 ± 9.6 NS
EVLW, extravascular lung water; ITBV, intrathoracic blood volume.
Table 6.Change of PVPI after Carperitide Therapy
Case Before (mL/kg) After (mL/kg) pvalue
ITBV normal group
Case 1 3.4 1.8
Case 2 3.3 2.6
Case 3 2.8 1.2
Case 4 3.1 2.9
Case 5 3.5 1.5
Case 6 2.8
Average 3.2 ± 0.3 2.1 ± 0.7 NS
ITBV abnormal group
Case 7 1.8 1.4
Case 8 3.2 4.2
Case 9 1.6 1.9
Case 10 2.7 3.4
Average 2.3 ± 0.8 2.7 ± 1.3 NS
PVPI, pulmonary vascular permeability index; ITBV, intrathoracic blood volume.
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Fig. 4. Change of chest X-ray findings after HANP therapy (case 7). Pre treatment: The chest X-ray permeability finding was abnormal. Post
treatment: The abnormal ITBV cases showed no improvement of the EVLW, and the PaO2/FiO2 ratio was not correlated with the chest X-ray
permeability findings.





Fig. 3. Changes of chest X-ray findings after carperitide therapy (case 2). Pre treatment: The chest X-ray permeability finding was abnormal. Post
treatment: The normal ITBV cases showed improvement of the EVLW, and the PaO2/FiO2ratio was correlated with the improvement of the chest X-
ray permeability findings just like case 1.





Fig. 2. Changes of chest X-ray findings after carperitide therapy (case 1). Pre treatment: The chest X-ray permeability finding was abnormal.  Post
treatment: The normal ITBV cases showed improvement of the EVLW, and the PaO2/FiO2ratio was correlated with the improvement of the chest X-ray
permeability findings.




PaO2/FiO2ratio 233water removal by continuous hemodiafiltration.
Pulmonary edema is one of the most common problems
in critically ill patients and has a significant influence on
the outcome of their health. However, it is difficult to
precisely diagnose low permeability on the chest X-ray in
patients with respiratory distress. The PiCCO
TM system
allows monitoring of the intravascular volume status and
can be used to guide volume therapy in patients with
pulmonary edema. We showed that the PiCCO
TM system
might be a useful device for the management of pulmo-
nary edema using HANP.
The limitations of this study were its retrospective design,
small sample size, and lack of a control group. Nonetheless,
we demonstrated the efficacy of HANP and usefulness of
the PiCCO
TM system in pulmonary edema patients. 
Many conditions limiting the usefulness of systems
using dilution methods, such as the PiCCO
TM system,
under experimental conditions, have been described, which
may lead to an underestimation of the EVLW. These
conditions include large pulmonary vascular obstruction,
focal lung injury, and lung resection.
12 Patients with the
above conditions were not included for our examination. 
HANP supplementation may improve the EVLW and
PVPI in pulmonary edema patients without heart disease
with a normal ITBV. The PiCCO
TM system seems to be a
useful device for the management of pulmonary edema in
critically ill patients.
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Fig. 5. Changes of chest X-ray findings after HANP therapy (case 8). Pre treatment: The chest X-ray permeability finding was abnormal. Post
treatment: The abnormal ITBV cases showed no improvement of the EVLW, and the PaO2/FiO2 ratio was not correlated with the chest X-ray
permeability findings just like case 7.
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